Avalo Therapeutics, Inc. (AVTX:NASDAQ) closed at $11.27 on October 16, 2026, down 6.16% on the day. The stock trades 53.6% below its 52-week high of $24.27 and 0.3% above its 52-week low of $11.24. Over the past year, it lost 26.6%. Avalo Therapeutics, Inc. is part of the Health Care sector.
| 5D | 1M | 3M | 6M | 1Y |
|---|---|---|---|---|
| -14.88% | -32.47% | -38.11% | -23.12% | -26.58% |
In 252 trading sessions since October 16, 2025, AVTX closed higher on 116 days (46%). Its best day was May 6, 2026 (+34.13%) and its worst was December 1, 2025 (-11.68%). The stock moved 10% or more in a single session 12 times. It opened at least 5% above the previous day's high 1 time.
Avalo Therapeutics Inc is a clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical needs in immunology, immuno-oncology, and rare genetic diseases. Its pipeline consists of product candidates advancing in development with ongoing clinical programs: AVTX-002, AVTX-007, AVTX-006, AVTX 800 programs (AVTX-801, AVTX-802, and AVTX-803).
Find more stocks like AVTX with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.